Patients With CP-CML Deemed Less Likely to Continue Taking Generic Imatinib

In a Canadian matched cohort study, intolerance drove patients with CP-CML to switch from generic imatinib at a higher frequency compared with those given brand-name products.

from Latest articles from Cancer Therapy Advisor Hematologic Cancers http://bit.ly/2tqGJwQ